Splenic masses in dogs are common, often discovered incidentally or after acute collapse, and the distinction between malignant hemangiosarcoma and benign masses significantly affects prognosis and welfare decisions.
Splenic hemangiosarcoma creates a welfare dilemma around uncertainty and prognosis: owners who pursue surgery without knowing whether the mass is benign or malignant face the possibility of subjecting a dog with a terminal cancer to major surgery that extends life only briefly. However, the only way to definitively distinguish benign from malignant is histopathology of the removed spleen, creating a circular challenge. Acute collapse from splenic rupture is a traumatic emergency for both dog and owner - the dog experiences cardiovascular shock while the owner faces urgent, high-stakes decisions without preparation. Dogs who survive splenectomy for hemangiosarcoma face a difficult trajectory: the brief survival period is often punctuated by additional bleeding events from metastatic disease. Quality of life in the post-surgical period is a key consideration, and chemotherapy decisions must weigh side effect burden against modest survival extension.